{"id":"pcv13i","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PCV13i works by introducing inactivated fragments of the pneumococcal capsular polysaccharides to the body, which triggers the production of antibodies that can recognize and neutralize the corresponding serotypes of S. pneumoniae. This immune response helps to prevent invasive pneumococcal disease, including pneumonia, meningitis, and sepsis.","oneSentence":"PCV13i is a conjugate vaccine that stimulates the body's immune response to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:53.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F"}]},"trialDetails":[{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT04100772","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-05-18","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PCV13i","genericName":"PCV13i","companyName":"CanSino Biologics Inc.","companyId":"cansino-biologics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"PCV13i is a conjugate vaccine that stimulates the body's immune response to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F. Used for Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}